Porton Fine Chemicals Ltd (300363.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100001S57

Price
21.99 CNY
Market cap
11.95 bn CNY
P/E (2025)
124.04
P/S (2025)
3.49
Dividend yield
0.41 %
Net margin
2.82 %
Return on equity (ROE)
1.80 %
Return on assets (ROA)
1.13 %

Porton Fine Chemicals Ltd financials

Fiscal year20242025
Revenue3.01 bn CNY3.42 bn CNY
Gross profit702.62 m CNY1.02 bn CNY
Operating income-342.50 m CNY211.03 m CNY
EBIT-224.00 m CNY133.15 m CNY
Net income-287.75 m CNY96.34 m CNY
Diluted EPS – continuing operations-0.53 CNY0.18 CNY

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Porton Fine Chemicals Ltd

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial in China and internationally. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling. Porton Pharma Solutions Ltd. was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. The company was incorporated in 2005 and is headquartered in Chongqing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.